Naltrexone beyond Psychiatric Domain
Naltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders. However, with the discovery of nonneuropsychiatric effects of OR signaling with low-dose naltrexone, it has found novel applicatio...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-10-01
|
| Series: | Indian Journal of Medical Specialities |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/injms.injms_35_22 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849224424309391360 |
|---|---|
| author | Ashutosh Garg Khyati Thapliyal Vivek Pal Singh |
| author_facet | Ashutosh Garg Khyati Thapliyal Vivek Pal Singh |
| author_sort | Ashutosh Garg |
| collection | DOAJ |
| description | Naltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders. However, with the discovery of nonneuropsychiatric effects of OR signaling with low-dose naltrexone, it has found novel applications in inflammatory, malignant, insulin sensitivity-related, and chronic pain conditions. Lower doses also ameliorate its adverse effects. Its off-label use in the abovementioned situations has proven to be cost-effective against costly immunomodulating and antineoplastic drugs. Its lower cost and miniscule margin of interest have precluded in-depth analysis by the pharmaceutical industry. So far, only animal studies, cell culture studies, and case reports have been conducted, some of which exhibit promising benefits. There is a dearth of much-needed quality trials. |
| format | Article |
| id | doaj-art-2a2eb19eaab74cd9948f1aff4ec0440b |
| institution | Kabale University |
| issn | 0976-2884 0976-2892 |
| language | English |
| publishDate | 2022-10-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Medical Specialities |
| spelling | doaj-art-2a2eb19eaab74cd9948f1aff4ec0440b2025-08-25T08:38:34ZengWolters Kluwer Medknow PublicationsIndian Journal of Medical Specialities0976-28840976-28922022-10-0113421121510.4103/injms.injms_35_22Naltrexone beyond Psychiatric DomainAshutosh GargKhyati ThapliyalVivek Pal SinghNaltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders. However, with the discovery of nonneuropsychiatric effects of OR signaling with low-dose naltrexone, it has found novel applications in inflammatory, malignant, insulin sensitivity-related, and chronic pain conditions. Lower doses also ameliorate its adverse effects. Its off-label use in the abovementioned situations has proven to be cost-effective against costly immunomodulating and antineoplastic drugs. Its lower cost and miniscule margin of interest have precluded in-depth analysis by the pharmaceutical industry. So far, only animal studies, cell culture studies, and case reports have been conducted, some of which exhibit promising benefits. There is a dearth of much-needed quality trials.https://journals.lww.com/10.4103/injms.injms_35_22alcoholinflammatiovinsulinmalignancyopioid |
| spellingShingle | Ashutosh Garg Khyati Thapliyal Vivek Pal Singh Naltrexone beyond Psychiatric Domain Indian Journal of Medical Specialities alcohol inflammatiov insulin malignancy opioid |
| title | Naltrexone beyond Psychiatric Domain |
| title_full | Naltrexone beyond Psychiatric Domain |
| title_fullStr | Naltrexone beyond Psychiatric Domain |
| title_full_unstemmed | Naltrexone beyond Psychiatric Domain |
| title_short | Naltrexone beyond Psychiatric Domain |
| title_sort | naltrexone beyond psychiatric domain |
| topic | alcohol inflammatiov insulin malignancy opioid |
| url | https://journals.lww.com/10.4103/injms.injms_35_22 |
| work_keys_str_mv | AT ashutoshgarg naltrexonebeyondpsychiatricdomain AT khyatithapliyal naltrexonebeyondpsychiatricdomain AT vivekpalsingh naltrexonebeyondpsychiatricdomain |